“This is one of the great heartbreaks in my life.” Peter Navarro says he had 65 million hydroxychloroquine tablets ready for distribution during COVID before opposition from Dr. Fauci and the FDA brought his efforts to a halt. He believes President Trump was headed for a landslide reelection before COVID, and that Dr. Fauci and major media outlets helped turn the pandemic into a political battle against him. “I literally had 65 million tablets of hydroxychloroquine that I was in the process of moving into the distribution channels.” “Those things were on the way when the hydroxy hysteria motivated by Dr. Fauci and implemented by the FDA hit and ground that to a halt.” “In his diary he says, ‘Use hydroxy. It’s safe. It’s worth trying it.’” “Prior to the pandemic hitting, President Trump was a shoo-in for a landslide victory.” “I think once the pandemic hit, the left realized, particularly the media, the CNNs, the MSNBCs, and all of that, they saw a vulnerability to blame Trump for the pandemic.” @RealPNavarro

This recognition is long overdue, but it is encouraging to see leadership taking steps to acknowledge and prioritize those injured by vaccines. This is an important step in the right direction. Transparency, accountability, and truly listening to those affected must remain at the heart of moving forward.

17 year old was hospitalized with Guillain-Barre Syndrome, with ascending weakness beginning in his legs and progressing to upper extremities and bulbar muscles, 10 days after receiving a COVID and flu shot.

Dr. Ryan Cole on Pneumonic Plague Headlines: “Don’t Live in Fear” This morning, IMA Head of Medical and Scientific Affairs Dr. Ryan Cole (@DoctorCole) joined host @janjeffcoat on The National Desk (@TND) to discuss recent reports of a suspected pneumonic plague case in Russia—and why there's no reason for public alarm. With no confirmed plague diagnosis or evidence of an outbreak, Dr. Cole emphasizes the importance of transparency, accurate information, and separating fact from speculation. Watch now.

This is an interesting article about how Russia has been cooperating with China on sensitive and dangerous biological research. (But, remember, so were we). And still nobody has been held accountable.

What if some of the most promising tools for managing pain didn’t come with a hefty price tag? There’s big money in pharmaceuticals…but not much in whole-grains or herbs and spices. How Not to Hurt will be released on December 15:

This week, I joined @NIHDirector_Jay, @DrOzCMS, and @DrSchwartzCDC at NIH to open a historic clinic dedicated to studying and caring for patients experiencing health problems following vaccination. We must listen to patients and families who report vaccine injuries—not dismiss or gaslight them. President Trump and I are building a health system that takes them seriously, follows the evidence, and uses what we learn to make vaccines safer. This is how we earn back trust in our public health institutions.

Paywall at The New York Times. Not worth the paper it used to be printed on. @nytimes Sad 😔 The future for public health is to get the government out of it altogether. Paying our taxes to fund government programs that are bought and paid for by conflicted entities has not been a viable solution. @AAPSonline @Honest_Medicine

Listen to my latest, original Sharyl Attkisson podcast to hear "The ABCs of Kratom." I try to fill in some blanks so that when you hear about this chemical or related drugs, you can understand what it's all about. The types of products and drugs associated with Kratom vary widely. The regulations are confused and confusing. What's the difference between the "natural" leaf and the synthetic kinds sold at gas stations?

Paywall at The New York Times. Not worth the paper it used to be printed on. @nytimes Sad 😔 The future for public health is to get the government out of it altogether. Paying our taxes to fund government programs that are bought and paid for by conflicted entities has not been a viable solution. @AAPSonline @Honest_Medicine

Competition forces businesses to lower prices and improve service. Healthcare should work the same way. That's why hospital contracts that limit competition deserve far more scrutiny.

I love 340B. As a nonprofit hospital administrator, I consider it one of the great miracles of American healthcare. It started as a program to help poor patients get access to medicine. Beautiful. Then we found the spread. I buy the drug at the 340B discount. I bill the commercial plan at the regular rate. I keep the difference. The patient gets the deductible. The employer gets the renewal increase. The manufacturer gets blamed. I get a new tower. That is called mission. And the best part? I don’t have to pass the savings to the patient. I don’t have to pass the savings to the employer. I don’t have to lower premiums. I don’t have to prove the vulnerable patient ever saw a dime. I just say “access” three times, put “community benefit” in the annual report, and everyone nods like I’m running a soup kitchen with oncology margins. Then came dual classification. Urban hospital? No problem. I’m rural now. Yes, my hospital is in Manhattan. Yes, my campus sits on billions of real estate. Yes, my lobby looks like a Four Seasons. But on paper? Country doctor. Dusty road. Single stoplight. Maybe a cow. That’s the business model. Rural when I want the subsidy. Urban when I want the commercial rates. Nonprofit when I want the tax exemption. Monopoly when I negotiate with employers. Charity when Congress asks questions. Private equity when I buy physician practices. Wall Street when BlackRock underwrites my bonds. Mission when the reporter calls. This is why I love 340B. Manufacturer must provide the discount. Employers pays full freight. Patients pays out of pocket. I keeps the arbitrage. Then I build a cancer tower and call it hope. Do I pass the 340B discount to the self-funded employer? No. Do I pass it to the fully insured commercial plan? Absolutely not. Do I use it to make healthcare cheaper? Please. I’m a nonprofit hospital administrator. Not a threat to my own margin. In 2024, 340B purchases hit $81.4 billion. That’s scale. I call it stewardship. And I serve vulnerable populations. Use the correct language. Now excuse me. I have to explain why my nonprofit hospital needs another tax exemption, another rate increase, another physician acquisition, another rural designation, and another debt issuance. The poor are counting on me. I love the US taxpayer…